IPRAGLIFLOZIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H21FO5S
Molecular Weight	404.452
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC=C(F)C(CC3=CC4=C(S3)C=CC=C4)=C2

InChI

InChIKey=AHFWIQIYAXSLBA-RQXATKFSSA-N

InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H21FO5S
Molecular Weight	404.452
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.astellas.com/en/news/10121 | https://www.medscape.com/viewarticle/819447 | https://www.ncbi.nlm.nih.gov/pubmed/25685284 | https://www.ncbi.nlm.nih.gov/pubmed/24668021

Ipragliflozin is an orally active, next-generation sodium glucose transporter-2 (SGLT2) inhibitor that has been developed by Astellas Pharma and Kotobuki. SGLTs are membrane proteins exist on the cell surface and transfer glucose into cells. SGLT2 is one subtype of SGLTs that plays a key role in the reuptake of glucose in the the proximal tubule of the kidneys. By selectively inhibiting SGLT2, Ipragliflozin suppresses the reuptake of glucose and reduces blood glucose levels. Ipragliflozin received marketing approval for the indication of type 2 diabetes under the brand name Suglat® Tablets in January 2014 and has been on the market since April 2014.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/glucose cotransporter 2 25 Target ID: CHEMBL3884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22507206	Inhibitor 8297		7.38 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259

PubMed

Title	Date	PubMed
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.	2011 Dec	21854192
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.	2012 Apr	22139434
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.	2012 Aug	22795925

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage is 50 mg of ipragliflozin orally administered once daily before or after breakfast. The dose may be increased up to 100 mg once daily with careful monitoring of the patient’s clinical course in the case of inadequate efficacy.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:56:56 GMT 2023` Edited by `admin` on `Sat Dec 16 17:56:56 GMT 2023`
Record UNII	3N2N8OOR7X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IPRAGLIFLOZIN

Official Name

English

D-GLUCITOL, 1,5-ANHYDRO-1-C-(3-(BENZO(B)THIEN-2-YLMETHYL)-4-FLUOROPHENYL)-, (1S)-

Common Name

English

ASP-1941

Code

English

ipragliflozin [INN]

Common Name

English

(1S)-1,5-ANHYDRO-1-C-(3-((1-BENZOTHIOPHEN-2-YL)METHYL)-4-FLUOROPHENYL)-D-GLUCITOL

Common Name

English

IPRAGLIFLOZIN [MI]

Common Name

English

Ipragliflozin [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A10BK05